Skip to content

Study · Randomized controlled trial · n = 70 · 2018

7 results

l-Carnosine As an Adjunctive Therapy to Risperidone in Children with Autistic Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial.

Hajizadeh-Zaker R, Ghajar A, Mesgarpour B, Afarideh M, Mohammadi MR, Akhondzadeh S

Journal of child and adolescent psychopharmacology13 Oct 2017Cited by 27 (Europe PMC)

PMID29027815 (opens in a new tab)DOI10.1089/cap.2017.0026 (opens in a new tab)PepBankPUB-29027815
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In children with ASD receiving risperidone, carnosine did not significantly affect the time-by-treatment interaction for irritability versus placebo.

    In plain wordsIn children with autism receiving risperidone, carnosine did not significantly change irritability over time compared with placebo.

    Peptide
    L-carnosine
    Outcome
    No significant changeABC-C irritability interaction
    Study

    n = 70

    Comparator
    placebo plus risperidone
    Analysis
    Primary
    Outcome group
    Autism core symptoms · Nervous system and cognition
    Studied dose
    800 mg/day in 2 divided doses · 10 weeksAs given in this study (human).

    Source sentences

    Summary
    Using the general linear model repeated measures, no significant effect was observed for time × treatment interaction on the irritability subscale scores.
    4 context sentences
    Summary · context
    The primary outcome measure was the mean change in the ABC-C irritability subscale score, and other subscale scores were defined as secondary outcomes.
    Summary · context
    This was a 10-week, randomized, double-blind, placebo-controlled study.
    Summary · context
    Seventy drug-free children aged 4-12 years old with a diagnosis of autism spectrum disorder (ASD), according to the Diagnostic and Statistical Manual of Mental Disorders, fifth edition.
    Summary · context
    The patients were randomly assigned to l-carnosine (800 mg/day in 2 divided doses) or placebo in addition to risperidone titrated up to 2 mg/day (based on body weight) for 10 weeks.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In children with ASD receiving risperidone, carnosine produced no significant improvement in lethargy/social withdrawal versus placebo.

    In plain wordsIn children with autism receiving risperidone, carnosine did not significantly improve lethargy/social withdrawal compared with placebo.

    Peptide
    L-carnosine
    Outcome
    No significant changeLethargy/social withdrawal
    Study

    n = 70

    Comparator
    placebo plus risperidone
    Analysis
    Secondary
    Outcome group
    Autism core symptoms · Nervous system and cognition
    Studied dose
    800 mg/day in 2 divided doses · 10 weeksAs given in this study (human).

    Source sentences

    Summary
    No significant improvements were obtained on the lethargy/social withdrawal, stereotypic behavior, and inappropriate speech subscale scores.
    4 context sentences
    Summary · context
    The primary outcome measure was the mean change in the ABC-C irritability subscale score, and other subscale scores were defined as secondary outcomes.
    Summary · context
    This was a 10-week, randomized, double-blind, placebo-controlled study.
    Summary · context
    Seventy drug-free children aged 4-12 years old with a diagnosis of autism spectrum disorder (ASD), according to the Diagnostic and Statistical Manual of Mental Disorders, fifth edition.
    Summary · context
    The patients were randomly assigned to l-carnosine (800 mg/day in 2 divided doses) or placebo in addition to risperidone titrated up to 2 mg/day (based on body weight) for 10 weeks.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In children with ASD receiving risperidone, carnosine produced no significant improvement in stereotypic behavior versus placebo.

    In plain wordsIn children with autism receiving risperidone, carnosine did not significantly improve stereotypic behavior compared with placebo.

    Peptide
    L-carnosine
    Outcome
    No significant changeStereotypic behavior
    Study

    n = 70

    Comparator
    placebo plus risperidone
    Analysis
    Secondary
    Outcome group
    Autism core symptoms · Nervous system and cognition
    Studied dose
    800 mg/day in 2 divided doses · 10 weeksAs given in this study (human).

    Source sentences

    Summary
    No significant improvements were obtained on the lethargy/social withdrawal, stereotypic behavior, and inappropriate speech subscale scores.
    4 context sentences
    Summary · context
    The primary outcome measure was the mean change in the ABC-C irritability subscale score, and other subscale scores were defined as secondary outcomes.
    Summary · context
    This was a 10-week, randomized, double-blind, placebo-controlled study.
    Summary · context
    Seventy drug-free children aged 4-12 years old with a diagnosis of autism spectrum disorder (ASD), according to the Diagnostic and Statistical Manual of Mental Disorders, fifth edition.
    Summary · context
    The patients were randomly assigned to l-carnosine (800 mg/day in 2 divided doses) or placebo in addition to risperidone titrated up to 2 mg/day (based on body weight) for 10 weeks.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In children with ASD receiving risperidone, carnosine produced no significant improvement in inappropriate speech versus placebo.

    In plain wordsIn children with autism receiving risperidone, carnosine did not significantly improve inappropriate speech compared with placebo.

    Peptide
    L-carnosine
    Outcome
    No significant changeInappropriate speech
    Study

    n = 70

    Comparator
    placebo plus risperidone
    Analysis
    Secondary
    Outcome group
    Autism core symptoms · Nervous system and cognition
    Studied dose
    800 mg/day in 2 divided doses · 10 weeksAs given in this study (human).

    Source sentences

    Summary
    No significant improvements were obtained on the lethargy/social withdrawal, stereotypic behavior, and inappropriate speech subscale scores.
    4 context sentences
    Summary · context
    The primary outcome measure was the mean change in the ABC-C irritability subscale score, and other subscale scores were defined as secondary outcomes.
    Summary · context
    This was a 10-week, randomized, double-blind, placebo-controlled study.
    Summary · context
    Seventy drug-free children aged 4-12 years old with a diagnosis of autism spectrum disorder (ASD), according to the Diagnostic and Statistical Manual of Mental Disorders, fifth edition.
    Summary · context
    The patients were randomly assigned to l-carnosine (800 mg/day in 2 divided doses) or placebo in addition to risperidone titrated up to 2 mg/day (based on body weight) for 10 weeks.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In children with ASD receiving risperidone, carnosine reduced hyperactivity/noncompliance scores significantly more than placebo at trial end.

    In plain wordsIn children with autism receiving risperidone, carnosine reduced hyperactivity/noncompliance scores more than placebo at trial end.

    Peptide
    L-carnosine
    Outcome
    DecreaseHyperactivity/noncompliance at trial end
    Study

    n = 70

    Comparator
    placebo plus risperidone
    Analysis
    Secondary
    Outcome group
    Autism core symptoms · Nervous system and cognition
    Studied dose
    800 mg/day in 2 divided doses · 10 weeksAs given in this study (human).

    Source sentences

    Summary
    Significantly greater score reduction in the hyperactivity/noncompliance subscale occurred in the l-carnosine group compared with the placebo group at the end of the trial.
    4 context sentences
    Summary · context
    The primary outcome measure was the mean change in the ABC-C irritability subscale score, and other subscale scores were defined as secondary outcomes.
    Summary · context
    This was a 10-week, randomized, double-blind, placebo-controlled study.
    Summary · context
    Seventy drug-free children aged 4-12 years old with a diagnosis of autism spectrum disorder (ASD), according to the Diagnostic and Statistical Manual of Mental Disorders, fifth edition.
    Summary · context
    The patients were randomly assigned to l-carnosine (800 mg/day in 2 divided doses) or placebo in addition to risperidone titrated up to 2 mg/day (based on body weight) for 10 weeks.
  6. 06HumanRandomized controlled trialSafety outcome

    In children with ASD receiving risperidone, extrapyramidal symptom scores and changes did not differ between carnosine and placebo.

    In plain wordsIn children with autism receiving risperidone, movement symptom scores and changes did not differ between carnosine and placebo.

    Peptide
    L-carnosine
    Outcome
    No significant changeExtrapyramidal symptoms and changes
    Study

    n = 70

    Comparator
    placebo plus risperidone
    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    800 mg/day in 2 divided doses · 10 weeksAs given in this study (human).

    Source sentences

    Summary
    Extrapyramidal Symptom Rating Scale Scores and its changes did not differ between the two groups.
    3 context sentences
    Summary · context
    This was a 10-week, randomized, double-blind, placebo-controlled study.
    Summary · context
    Seventy drug-free children aged 4-12 years old with a diagnosis of autism spectrum disorder (ASD), according to the Diagnostic and Statistical Manual of Mental Disorders, fifth edition.
    Summary · context
    The patients were randomly assigned to l-carnosine (800 mg/day in 2 divided doses) or placebo in addition to risperidone titrated up to 2 mg/day (based on body weight) for 10 weeks.
  7. 07HumanRandomized controlled trialSafety outcome

    In children with ASD receiving risperidone, other side effect frequency did not differ significantly between carnosine and placebo.

    In plain wordsIn children with autism receiving risperidone, other side effects did not differ significantly between carnosine and placebo.

    Peptide
    L-carnosine
    Outcome
    No significant changeOther side effects
    Study

    n = 70

    Comparator
    placebo plus risperidone
    Outcome group
    Adverse events · Whole body
    Studied dose
    800 mg/day in 2 divided doses · 10 weeksAs given in this study (human).

    Source sentences

    Summary
    The frequency of other side effects was not significantly different between the two groups.
    3 context sentences
    Summary · context
    This was a 10-week, randomized, double-blind, placebo-controlled study.
    Summary · context
    Seventy drug-free children aged 4-12 years old with a diagnosis of autism spectrum disorder (ASD), according to the Diagnostic and Statistical Manual of Mental Disorders, fifth edition.
    Summary · context
    The patients were randomly assigned to l-carnosine (800 mg/day in 2 divided doses) or placebo in addition to risperidone titrated up to 2 mg/day (based on body weight) for 10 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.